Corindus Vascular Robotics, a developer of precision vascular robotics, received 510(k) marketing clearance from the FDA for use of its CorPath GRX System in peripheral vascular interventions.

The CorPath GRX system broadens the capabilities of the CorPath robotic technology platform from exclusively treating coronary artery disease to include peripheral artery disease.

The system allows the cardiologist to sit at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision.

"The ability to treat patients with PAD using CorPath GRX is a significant step for Corindus as we expand the usage of our technology beyond [percutaneous coronary intervention],” said Mark Toland, president and CEO of Corindus.